Evidence map›Paper›PMID 31694771›Full record

ArticleUltrasound in medicine & biology2020

Use of 3-D Contrast-Enhanced Ultrasound to Evaluate Tumor Microvasculature After Nanoparticle-Mediated Modulation.

Jihun Kwon, Rajalekha M Rajamahendiran, Needa A Virani, Sijumon Kunjachan, Erin Snay, Max Harlacher, Marios Myronakis, Shinichi Shimizu, Hiroki Shirato, Tomasz J Czernuszewicz and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ultrasound in medicine & biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Jihun KwonDepartment of Radiation Oncology, Hokkaido University, Sapporo, Hokkaido, Japan; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: jihun.k@frontier.hokudai.ac.jp.
Rajalekha M RajamahendiranSonoVol, Inc., Research Triangle Park, North Carolina, USA.
Needa A ViraniDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Sijumon KunjachanDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Erin SnayBoston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Max HarlacherSonoVol, Inc., Research Triangle Park, North Carolina, USA.
Marios MyronakisDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Shinichi ShimizuDepartment of Radiation Oncology, Hokkaido University, Sapporo, Hokkaido, Japan; Global Station for Quantum Medical Science and Engineering, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Hokkaido, Japan.
Hiroki ShiratoDepartment of Radiation Oncology, Hokkaido University, Sapporo, Hokkaido, Japan; Global Station for Quantum Medical Science and Engineering, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Hokkaido, Japan.
Tomasz J CzernuszewiczSonoVol, Inc., Research Triangle Park, North Carolina, USA.
Ryan GessnerSonoVol, Inc., Research Triangle Park, North Carolina, USA.
Ross BerbecoDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Harvard University · USSonoVol (United States) · USHokkaido University · JPDana-Farber Brigham Cancer Center · USDana-Farber Cancer Institute · US

Funding

Gold nanoparticles as vascular disruptig agents in radiation therapy of NSCLCR21CA188833 · NCI · DANA-FARBER CANCER INST · PI BERBECO, ROSS I. · 2015 to 2016
$396k
NCI NIH HHS R21 CA188833
6 · The paper itself

Abstract

A cost-effective method for serial in vivo imaging of tumor microvasculature has been developed. We evaluated acoustic angiography (AA) for visualizing and assessing non-small cell lung tumor (A549) microvasculature in mice before and after tumor vascular disruption by vascular-targeted gold nanoparticles and radiotherapy. Standard B-mode and microbubble-enhanced AA images were acquired at pre- and post-treatment time points. Using these modes, a new metric, 50% vessel penetration depth, was developed to characterize the 3-D spatial heterogeneity of microvascular networks. We observed an increase in tumor perfusion after radiation-induced vascular disruption, relative to control animals. This was also visualized in vessel morphology mode, which revealed a loss in vessel integrity. We found that tumors with poorly perfused vasculature at day 0 exhibited a reduced growth rate over time. This suggested a new method to reduce in-group treatment response variability using pre-treatment microvessel maps to objectively identify animals for study removal.

Indexed as

Contrast MediaImaging, Three-DimensionalMetal NanoparticlesMicrobubblesAngiographyAnimalsFemaleImage EnhancementMiceMicrovesselsNeoplasmsUltrasonographyContrast MediaAcoustic angiographyGold nanoparticlesMicrovasculatureRadiation therapyVascular disruption

Identifiers

PMID31694771
PMCPMC6930329
OpenAlexW2987540080

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.